Skip to main content
Premium Trial:

Request an Annual Quote

Orion and VBI Sign Diagnostic-Development Deal for Viral Pathogens

NEW YORK, Feb. 7 (GenomeWeb News) - The Virginia Bioinformatics Institute at Virginia Tech and Orion Integrated Biosciences plan to co-develop new diagnostic methods for viral pathogens, the partners said today.

 

Under the agreement, VBI will integrate data on encephalic and hemorrhagic viruses from its PathPort project into Orion's integrated computational analysis system.

 

"The lack of diagnostic tools that can integrate and analyze molecular surveillance data is a major gap in disease prevention and the development of countermeasure responses," said Oswald Crasta, director of bioinformatics for VBI's cyberinfrastructure group.

 

Financial details of the deal  were not provided.

 

VBI 's PathPort platform includes pathogens with the potential use as biological weapons, according to the statement.

 

New York-based Orion Integrated Biosciences is a drug-discovery and viral disease detection shop, focusing on the development of antiviral agents and devices that can recognize lethal pathogens in medical and military settings.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.